Charlottesville, VA – July 26, 2011 – Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company’s lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.  GBM is one of [...]

“This non-dilutive award will advance our clinical program and aid us in our mission to introduce approved novel and effective therapies as quickly as possible, providing new hope for patients with PAD, cancer and other conditions related to hypoxia,” said David G. Kalergis, CEO, Diffusion Pharmaceuticals.”

CHARLOTTESVILLE, VA –August 2, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes drug formulation and use claims relating to Diffusion’s entire family of first-in-class new chemical entities. [...]

CHARLOTTESVILLE, VA — June 6, 2006 — Diffusion Pharmaceuticals LLC, a drug discovery and development company, today announced that VaBIO, a membership organization that promotes the scientific and economic impact of the life sciences industry in the Commonwealth of Virginia, awarded it for the third year a $1,500 grant as part of the organization’s Summer [...]

Charlottesville, VA, June 15, 2005—The Virginia Piedmont Technology Council (VPTC), the most vibrant tech-focused business alliance in Central Virginia, elected its officers and board of directors for 2005-2006 at the Council’s annual membership lunch held on Wednesday, June 15. Outgoing Chair, Suzanne Jackson, President of Four Leaf Public Relations, handed the gavel to incoming Chair, [...]